West Coast Financial buys $7,119,560 stake in C R Bard Inc (BCR)

C R Bard Inc (BCR) : West Coast Financial scooped up 467 additional shares in C R Bard Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 2, 2016. The investment management firm now holds a total of 32,900 shares of C R Bard Inc which is valued at $7,119,560.C R Bard Inc makes up approximately 2.96% of West Coast Financial’s portfolio.

C R Bard Inc opened for trading at $215.18 and hit $216.87 on the upside on Friday, eventually ending the session at $216.4, with a gain of 0.40% or 0.87 points. The heightened volatility saw the trading volume jump to 3,20,758 shares. Company has a market cap of $15,866 M.

Other Hedge Funds, Including , Ifp Advisors Inc boosted its stake in BCR in the latest quarter, The investment management firm added 53 additional shares and now holds a total of 675 shares of C R Bard Inc which is valued at $146,070. C R Bard Inc makes up approx 0.01% of Ifp Advisors Inc’s portfolio.Granite Investment Advisors reduced its stake in BCR by selling 322 shares or 1.02% in the most recent quarter. The Hedge Fund company now holds 31,256 shares of BCR which is valued at $6,631,586. C R Bard Inc makes up approx 1.33% of Granite Investment Advisors’s portfolio.Trust Co Of Oklahoma boosted its stake in BCR in the latest quarter, The investment management firm added 2,481 additional shares and now holds a total of 12,179 shares of C R Bard Inc which is valued at $2,523,854. C R Bard Inc makes up approx 1.37% of Trust Co Of Oklahoma’s portfolio.

On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.

Many Wall Street Analysts have commented on C R Bard Inc. Company shares were Reiterated by Barclays on Apr 28, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 212 from a previous price target of $195 .C R Bard Inc was Initiated by Nomura to “Neutral” on Mar 17, 2016.

C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.

Leave a Reply

C R Bard Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on C R Bard Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.